One Equity Partners Agrees to Acquire Wheeler Fleet Solutions
One Equity Partners ('OEP'), a middle market private equity firm, today announced it has agreed to acquire Wheeler Fleet Solutions ('Wheeler' or 'the Company,'), a leading aftermarket parts distribution company, from VSE Corporation ('VSE') (NASDAQ: VSEC), a leading provider of aerospace aftermarket distribution and repair services.
Founded in 1960 and headquartered in Somerset, Pa., Wheeler Fleet Solutions is a leading parts distributor and engineering solutions provider servicing the medium and heavy-duty fleet market. Wheeler provides exceptional value to its customers by combining world-class customer service, parts expertise, proprietary IT solutions, and a complete line of medium and heavy-duty replacement parts. The Company employs approximately 385 people across three primary distribution centers in Pennsylvania, Mississippi and Texas.
'The acquisition of Wheeler Fleet Solutions is the latest example of OEP's ability to identify valuable industrial service assets from large corporations looking to streamline their operations through divestitures,' said Steve Lunau, Partner at One Equity Partners. 'OEP has a proven history of transforming industrial distribution businesses through strategic organic and inorganic investments that enhance operational performance, expand product capabilities, and extend geographic reach. We are committed to building on Wheeler Fleet Solution's strong employee and customer centric culture, while driving continued development and growth.'
'The Wheeler team looks forward to working with One Equity Partners and executing on our shared vision for Wheeler as an independent business,' said Chris Wheeler, President of Wheeler Fleet Solutions. 'OEP has expertise on scaling industrial aftermarket distribution businesses and holds a deep understanding of the specific trends at play within our sector.'
'We are excited to partner with Chris and his team for the next chapter of the Wheeler Fleet Solutions story. Truck fleets in North America are witnessing unprecedented levels of advancement and growing needs for parts and services. Wheeler, with 65 years of reputation for industry leading quality customer service, is well positioned to accelerate into its next phase of growth and development as a standalone enterprise,' said Ori Birnboim, Partner, One Equity Partners.
'OEP has a proven track record of successfully navigating the complexities of corporate carve-outs and scaling industrial services businesses,' said John Cuomo, President and CEO of VSE Corporation. 'I am confident that the Wheeler Fleet Solutions business and team will thrive under OEP's leadership, benefiting from their strong culture and strategic vision. I am deeply grateful to the Wheeler team for their dedication and contributions, and I look forward to seeing the continued success they will achieve together with OEP.'
Moelis & Company LLC acted as exclusive financial advisor and Davis Polk & Wardwell LLP served as legal counsel to One Equity Partners. Jefferies, LLC acted as exclusive financial advisor to VSE Corporation.
About One Equity Partners
One Equity Partners ('OEP') is a middle market private equity firm focused on the industrial, healthcare, and technology sectors in North America and Europe. The firm seeks to build market-leading companies by identifying and executing transformative business combinations. OEP is a trusted partner with a differentiated investment process, a broad and senior team, and an established track record generating long-term value for its partners. Since 2001, the firm has completed more than 400 transactions worldwide. OEP, founded in 2001, spun out of JP Morgan in 2015. The firm has offices in New York, Chicago, Frankfurt and Amsterdam. For more information, please visit www.oneequity.com. Wheeler Fleet Solutions ('Wheeler') began as Wheeler Bros. in 1960 as a small engine repair shop in Somerset, Pennsylvania. From those roots, the company has grown into a fleet-focused parts distribution and services company with over 300 employees. Wheeler Fleet Solutions ships over three million line items yearly to 700 managed inventory stock rooms and thousands of B2B customers across the United States. Wheeler offers a huge selection of parts as well as stockroom and inventory management services, fleet management software and curated custom-engineered service parts. Whether you're delivering mail, food or freight, Wheeler has a solution for you. Learn more at www.wheelerfleet.com.
.
CONTACT: Media
Thomas Zadvydas
Stanton
646-502-3538
SOURCE: One Equity Partners
Copyright Business Wire 2025.
PUB: 02/18/2025 07:35 AM/DISC: 02/18/2025 07:37 AM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
29 minutes ago
- Yahoo
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
29 minutes ago
- Yahoo
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
